METTL3 is known to promote cell cycle progression in cancers like HNSCC and bladder cancer [31, 32] and it regulates cell cycle markers such as CDK2 (cyclin-dependent kinase 2) and Cyclin D1 in gastrointestinal stromal tumors [33]. This evidence concerns the gene CDK2 and urinary bladder carcinoma.